ANO

0.00%

77.0¢ advance zinctek limited

Who was that fanboy from a few years back @vestro or something?...

First 3 Last

Share
Profile

Follow
Bayd76

310 Posts.

83

12/07/24

16:58

Post #: 74731041
Share

Originally posted by flobob: ↑

the business seems to go nowhere.
- revenue growth is negative and initiatives end pretty fast after initiation. can we expect anything from these initiatives or is it more something like: "we try with little money but do not expect much from it - if it works we make a lot of money, if not it's fine"?
- loosing market share after loosing important customer in the USA and not being aware of it
- leadership is questionable - paying out unearned dividends in part in new shares to show a "return" to shareholders and the market is odd.
- lacking sound strategy and miserable execution of those aspects that would make sense on paper.
- their main product - zinc oxide for mineral sunscreens is not superior to other products on the market and a commodity. switching and reformulating is not an issue.
- pushing for cost cuts cannot go on forever and is short lived especially with decreasing revenue
- after realizing their predictions are unreliable management went into hiding mode and limits itself to admit once a year that the results are disappointing and PRs that are required by law.
- consumer behavior pushing towards the adoption of mineral sunscreen is not happening in a meaningful way and legal changes in favor of it might never happen
- free cash flow generation is barely positive given the shrinking revenue, rising costs and the never ending increase in working capital (unsold inventory sitting in various warehouses globally).
- ROCE has been falling because EBIT growth is negative while the company invested millions in growing capacity that is unused (and will probably be written off)

objectively, the business is more or less a mess, but why did the majority shareholder buy shares at much higher valuations over the past years? he should know the business better than anyone else and apparently got his thesis wrong...
how could they loose their main customer? they always talked about increasing the number of distributors to gain new clients and all the sudden they loose their main one ...

the best managements I have seen are transparent and communicate with their shareholders.
TJ Rodgers from Enovix and Enphase is a perfect role model. He communicates the positives and negatives and has a clear strategy and milestones.

Maybe ANO has nothing to say and has no way out.
the fact that the stock plummeted and there is no interest in the company leads toward that conclusion.
Or they work in secret and surprise us one day (I assign a probability of 1% to this scenario)

Expand

Who was that fanboy from a few years back @vestro or something? Another pumper? He's long gone I'm sure.

ANO Price at posting: 72.0¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 1 more message in this thread...

First 3 Last

Add ANO (ASX) to my watchlist

(20min delay)
Last 77.0¢		Change 0.000(0.00%)		Mkt cap ! $48.08M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	5273	77.0¢

Sellers (Offers)

Price($)	Vol.	No.
90.0¢	5250	2

View Market Depth

No.	Vol.	Price($)
1	5273	0.770
1	49122	0.760
1	24	0.730
1	42952	0.720
1	714	0.700

Price($)	Vol.	No.
0.900	5250	2
0.950	5000	1
1.000	11450	2
1.050	5000	1
0.000	0	0

Last trade - 16.12pm 04/10/2024 (20 minute delay)

ANO (ASX) Chart

Day chart unavailable

Who was that fanboy from a few years back @vestro or something?...

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Who was that fanboy from a few years back @vestro or something?...

Top Stories

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News